LifeVantage (NASDAQ:LFVN) Shares Cross Above 200-Day Moving Average – Time to Sell?

LifeVantage Co. (NASDAQ:LFVN)’s share price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $15.57 and traded as high as $17.64. LifeVantage shares last traded at $17.04, with a volume of 153,399 shares changing hands.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on LFVN shares. Craig Hallum started coverage on shares of LifeVantage in a research report on Tuesday, January 14th. They set a “buy” rating and a $35.00 price target for the company. Lake Street Capital started coverage on shares of LifeVantage in a research report on Thursday, December 19th. They set a “buy” rating and a $26.00 price target for the company.

LifeVantage Trading Up 0.1 %

The firm has a market capitalization of $213.87 million, a P/E ratio of 30.43 and a beta of 0.74. The company’s fifty day simple moving average is $19.80 and its 200 day simple moving average is $15.57.

LifeVantage (NASDAQ:LFVN) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $0.22 EPS for the quarter, topping the consensus estimate of $0.14 by $0.08. LifeVantage had a net margin of 3.46% and a return on equity of 34.29%.

LifeVantage Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, March 17th. Investors of record on Monday, March 3rd were given a dividend of $0.04 per share. The ex-dividend date was Monday, March 3rd. This represents a $0.16 dividend on an annualized basis and a yield of 0.94%. LifeVantage’s dividend payout ratio (DPR) is currently 28.57%.

Insider Activity at LifeVantage

In related news, Director Raymond B. Greer sold 8,000 shares of LifeVantage stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $20.15, for a total transaction of $161,200.00. Following the completion of the transaction, the director now directly owns 99,288 shares of the company’s stock, valued at $2,000,653.20. This trade represents a 7.46 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 20.65% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. Copeland Capital Management LLC bought a new stake in LifeVantage during the fourth quarter valued at approximately $65,000. Hillsdale Investment Management Inc. boosted its position in shares of LifeVantage by 7.3% in the fourth quarter. Hillsdale Investment Management Inc. now owns 14,720 shares of the company’s stock worth $258,000 after purchasing an additional 1,000 shares during the period. Schonfeld Strategic Advisors LLC bought a new position in shares of LifeVantage in the fourth quarter worth approximately $282,000. OMERS ADMINISTRATION Corp bought a new position in shares of LifeVantage in the fourth quarter worth approximately $284,000. Finally, Barclays PLC boosted its position in shares of LifeVantage by 38.2% in the third quarter. Barclays PLC now owns 41,966 shares of the company’s stock worth $507,000 after purchasing an additional 11,608 shares during the period. 35.32% of the stock is owned by hedge funds and other institutional investors.

LifeVantage Company Profile

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.